Subscribe
Call Us: 02380 97 07 33

Posts Tagged Drug Safety

Drug Alert: Amoxicillin Sodium 1g, 250mg and 500mg Powder for Solution for Injection – NOT FOR neonates and infants below one year old

Drug Alert: Amoxicillin Sodium 1g, 250mg and 500mg Powder for Solution for Injection – NOT FOR neonates and infants below one year old

by Kazeem Olalekan MRPharmS The Medicines and Healthcare products Regulatory Agency has just issued a Class 4 Drug Safety Alert for Wockhardt UK Ltd – Amoxicillin Sodium 1g, 250mg and 500mg Powder for Solution for Injection. Alert details Drug alert number EL (14)A/09 in connection with the […]

Read more

What’s New? The BNF and BNFc updates

What’s New? The BNF and BNFc updates

by Kazeem Olalekan A BNF and BNFc app convert like myself knows to press the ‘Update Now’ button whenever I am prompted to do so. It is the best way to be up-to-date in clinical decision making. What I thought I would do today is highlight some […]

Read more

Febuxostat (Adenuric) and hypersensitivity reaction

Febuxostat (Adenuric) and hypersensitivity reaction

by Kazeem Olalekan Attention has just been drawn to the Drug Safety Update on Febuxostat (Adenuric) via the PJOnline website. In summary, there have been rare but serious reports of hypersensitivity reactions, including Stevens-Johnson syndrome and acute anaphylactic shock, with febuxostat (Adenuric). Febuxostat must be stopped immediately […]

Read more

Take note: PPIs and emerging issues

Take note: PPIs and emerging issues

by Kazeem Olalekan MRPharmS In August 2009 we reported a potential interaction between Proton pump inhibitors (PPI) and Clopidogrel. Subsequent to that report, Lancet concluded that PPI does not interfere with the clinical benefits of clopidogrel. The case frustrated me because in one week I was asking […]

Read more

Drug Safety Alert – Dronedarone

Drug Safety Alert – Dronedarone

Dronedarone (Multaq▼) is an antiarrhythmic agent indicated in adult, clinically stable patients with history of, or current, non-permanent atrial fibrillation (AF) to prevent recurrence of AF or to lower ventricular rate. Dronedarone is available as a 400 mg film-coated tablet and the recommended dose is 400 mg […]

Read more

Disclaimer

The information on this site is provided 'as is' Whilst we stake our reputation on producing the most accurate information (and employ reasonable care and skill in providing this site's content), we cannot warrant that the information is accurate, complete and up to date. Neither can we guarantee uninterrupted performance and durability.
Click here to read our complete terms and conditions.